Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 2,407 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dysplasia Mild Clear all

Conditions: Alzheimer's Disease
Interventions: Tricaprilin, Placebo; Drug · Other
Lead sponsor: Cerecin; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 25
States / cities: Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more

Conditions: Alzheimer's Disease
Interventions: ABT-089; Drug
Lead sponsor: Abbott; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 22
States / cities: Phoenix, Arizona • Sun City, Arizona • Fresno, California + 19 more

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Beta amyloid imaging; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression, Pain, Cognitive Impairment
Interventions: PATH-Pain; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
Interventions: Resveratrol, Quercetin, and Curcumin (RQC), Curcumin; Drug
Lead sponsor: Zaparackas and Knepper LTD; Other
Eligibility: 50 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions: [F-18]Flornaptitril; Drug
Lead sponsor: CereMark Pharma, LLC; Industry
Eligibility: 45 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major, Depression Mild
Interventions: MEB-001; Device
Lead sponsor: Medibio Limited; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Bradenton, Florida • Blaine, Minnesota • Plymouth, Minnesota + 10 more

Conditions: Covid19
Interventions: Sotrovimab (Gen1), Sotrovimab (Gen2); Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Anniston, Alabama • Bakersfield, California • Northridge, California + 12 more

Conditions: Alzheimer's Disease
Interventions: MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 7
States / cities: Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Adherence
Interventions: Improving Cognitive Aging through Nutrition (ICAN) Adherence Program, Improving Cognitive Aging through Nutrition, Mediterranean diet; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Vestibular Diseases, Labyrinth Diseases, Ear Diseases, Otorhinolaryngologic Diseases, Traumatic Brain Injury
Interventions: Usual care physical therapy plus SEMD, Usual care physical therapy only; Device · Other
Lead sponsor: Karen L Atkins; Industry
Eligibility: 21 Years to 84 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Garden Grove, California • Celebration, Florida • Fort Myers, Florida + 1 more

Conditions: Mild Cognitive Impairment
Interventions: Atorvastatin Oral Tablet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease
Interventions: Interleukin-2, Placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 50 Years to 86 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild, Major Depression Moderate, Major Depression Severe
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Brain Injuries, Concussion, Mild, Concussion, Brain, Near Point Convergence, Concussion, Intermediate
Interventions: BrainScope Ahead 300iP-O, SCAT5, Near Point Convergence; Device · Diagnostic Test
Lead sponsor: BrainScope Company, Inc.; Industry
Eligibility: 13 Years to 50 Years
Enrollment: 1,318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Storrs, Connecticut • Miami, Florida + 3 more

Conditions: Mild-Moderate Alzheimer's Disease, Healthy Elderly
Interventions: MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Glendale, California • Long Beach, California • Panorama City, California + 7 more

Conditions: Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Renal Insufficiency
Interventions: QAW039, QAW39A, QAW39A2107; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Occupational Therapy, Epidemiology, Neurologic Disorder
Interventions: iSMART; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
Interventions: CerefolinNAC®; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Mild Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 65 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Severe or Mild Toxicity From Radiotherapy and/or Chemotherapy
Interventions: Blood Draw; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more

Search by objective public record fields.

Tricaprilin in Mild to Moderate Alzheimer's Disease

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.

A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD

RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

A Scalable Nutrition Adherence Intervention

Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Phase II Clinical Trial of Interleukin-2 in AD

MRS and Medication Response: A Pilot Study

Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

Interactive Self-Management Augmented by Rehabilitation Technologies

NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

Recovery Among Older Adults Following Mild TBI

Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis